Pfizer (PFE) announced the European Commission has approved ZIRABEV for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer, advanced and/or metastatic renal cell cancer and persistent, recurrent or metastatic carcinoma of the cervix. ZIRABEV is a biosimilar to Avastin, which is offered by Genentech, a unit of Roche (RHHBY). Andreas Penk, M.D., regional president, Oncology International Developed Markets at Pfizer, said, “We are proud that ZIRABEV was approved today as our second oncology biosimilar in Europe. This milestone reflects our ongoing commitment to biosimilars as we continue to bring high-quality medicines to market that may help generate cost savings for cancer care.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.